» Articles » PMID: 37629010

Glucagon and Its Receptors in the Mammalian Heart

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Aug 26
PMID 37629010
Authors
Affiliations
Soon will be listed here.
Abstract

Glucagon exerts effects on the mammalian heart. These effects include alterations in the force of contraction, beating rate, and changes in the cardiac conduction system axis. The cardiac effects of glucagon vary according to species, region, age, and concomitant disease. Depending on the species and region studied, the contractile effects of glucagon can be robust, modest, or even absent. Glucagon is detected in the mammalian heart and might act with an autocrine or paracrine effect on the cardiac glucagon receptors. The glucagon levels in the blood and glucagon receptor levels in the heart can change with disease or simultaneous drug application. Glucagon might signal via the glucagon receptors but, albeit less potently, glucagon might also signal via glucagon-like-peptide-1-receptors (GLP1-receptors). Glucagon receptors signal in a species- and region-dependent fashion. Small molecules or antibodies act as antagonists to glucagon receptors, which may become an additional treatment option for diabetes mellitus. Hence, a novel review of the role of glucagon and the glucagon receptors in the mammalian heart, with an eye on the mouse and human heart, appears relevant. Mouse hearts are addressed here because they can be easily genetically modified to generate mice that may serve as models for better studying the human glucagon receptor.

Citing Articles

Ubrogepant, erenumab, and eptinezumab antagonize positive inotropic effects of the calcitonin gene-related peptide in the isolated human atrium.

Neumann J, Hofmann B, Gergs U Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40085216 DOI: 10.1007/s00210-025-04029-7.


Glucagon Can Increase Force of Contraction via Glucagon Receptors in the Isolated Human Atrium.

Neumann J, Schmidt F, Hofmann B, Gergs U Int J Mol Sci. 2025; 26(2.

PMID: 39859412 PMC: 11765814. DOI: 10.3390/ijms26020698.


Evaluating sex-specific responses to western diet across the lifespan: impact on cardiac function and transcriptomic signatures in C57BL/6J mice at 530 and 640/750 days of age.

Stepanyan A, Brojakowska A, Zakharyan R, Hakobyan S, Davitavyan S, Sirunyan T Cardiovasc Diabetol. 2024; 23(1):454.

PMID: 39732652 PMC: 11682651. DOI: 10.1186/s12933-024-02565-9.


Bisphenol C Induces Cardiac Developmental Defects by Disrupting mA Homeostasis.

Su K, Liu J, Chen J, Wu H, Tang W, Sun S Environ Sci Technol. 2024; 58(39):17259-17269.

PMID: 39208335 PMC: 11447910. DOI: 10.1021/acs.est.4c04373.


GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms.

Mullur N, Morissette A, Morrow N, Mulvihill E J Endocrinol. 2024; 263(1).

PMID: 39145614 PMC: 11466209. DOI: 10.1530/JOE-24-0046.

References
1.
Ahren B . Glucagon--Early breakthroughs and recent discoveries. Peptides. 2015; 67:74-81. DOI: 10.1016/j.peptides.2015.03.011. View

2.
Andjelkovic I, Zlokovic B . Protective effects of glucagon during the anaphylactic response in guinea-pig isolated heart. Br J Pharmacol. 1982; 76(3):483-9. PMC: 2071802. DOI: 10.1111/j.1476-5381.1982.tb09243.x. View

3.
Pontiroli A, Calderara A, Perfetti M, Bareggi S . Pharmacokinetics of intranasal, intramuscular and intravenous glucagon in healthy subjects and diabetic patients. Eur J Clin Pharmacol. 1993; 45(6):555-8. DOI: 10.1007/BF00315314. View

4.
Chatelain P, Robberecht P, Waelbroeck M, De Neef P, CAMUS J, Huu A . Topographical distribution of the secretin- and VIP-stimulated adenylate cyclase system in the heart of five animal species. Pflugers Arch. 1983; 397(2):100-5. DOI: 10.1007/BF00582046. View

5.
Spinelli V, Sartiani L, Mugelli A, Romanelli M, Cerbai E . Hyperpolarization-activated cyclic-nucleotide-gated channels: pathophysiological, developmental, and pharmacological insights into their function in cellular excitability. Can J Physiol Pharmacol. 2018; 96(10):977-984. DOI: 10.1139/cjpp-2018-0115. View